Agios Pharmaceuticals Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Public

  • Employees
  • 488

Employees

  • Stock Symbol
  • AGIO

Stock Symbol

  • Share Price
  • $27.66
  • (As of Thursday Closing)

Agios Pharmaceuticals General Information

Description

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Contact Information

Website
www.agios.com
Formerly Known As
Cancer Metabolism Therapeutics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 88 Sidney Street
  • Cambridge, MA 02139-4169
  • United States
+1 (617)
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Stock Exchange
NAS
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 88 Sidney Street
  • Cambridge, MA 02139-4169
  • United States
+1 (617)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Agios Pharmaceuticals Stock Performance

As of 17-Apr-2025, Agios Pharmaceuticals’s stock price is $27.66. Its current market cap is $1.58B with 57.3M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$27.66 $27.14 $23.41 - $62.58 $1.58B 57.3M 693K $11.86

Agios Pharmaceuticals Financials Summary

As of 31-Dec-2024, Agios Pharmaceuticals has a trailing 12-month revenue of $36.5M.

In Thousands,
USD 		TTM 31-Dec-2024 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 930,089 930,089 672,709 904,096
Revenue 36,498 36,498 26,823 14,240
EBITDA 675,539 675,539 (378,809) (236,030)
Net Income 673,725 673,725 (352,088) (231,801)
Total Assets 1,663,199 1,663,199 937,118 1,238,718
Total Debt 56,988 56,988 71,996 85,659
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Agios Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Agios Pharmaceuticals‘s full profile, request access.

Request a free trial

Agios Pharmaceuticals Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion
Price		 % Owned

This information is available in the PitchBook Platform. To explore Agios Pharmaceuticals‘s full profile, request access.

Request a free trial

Agios Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create different
Pharmaceuticals
Cambridge, MA
488 As of 2024

Boston, MA
 

San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Agios Pharmaceuticals Competitors (58)

One of Agios Pharmaceuticals’s 58 competitors is Cue Biopharma, a Formerly VC-backed company based in Boston, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cue Biopharma Formerly VC-backed Boston, MA
Nektar Therapeutics Formerly VC-backed San Francisco, CA
ArriVent Biopharma Formerly VC-backed Newtown Square, PA
Dicerna Pharmaceuticals Formerly VC-backed Lexington, MA
BeiGene Formerly PE-Backed Beijing, China
You’re viewing 5 of 58 competitors. Get the full list »

Agios Pharmaceuticals Patents

  • 427

    Total Documents Applications and Grants

  • Total Patents Families

  • 243

    Granted

  • 57

    Pending

  • Expiring in next 12 mo

Agios Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20250074922-A1 Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations Pending 30-Aug-2023
US-20230365592-A1 Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations Pending 28-Feb-2022
US-20230339980-A1 Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations Active 28-Feb-2022
US-11919915-B2 Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations Active 28-Feb-2022
AU-2023225782-A1 Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations Pending 28-Feb-2022 C07D471/04
To view Agios Pharmaceuticals’s complete patent history, request access »

Agios Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Agios Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated October, 15, 2024

26.61 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,109

Rank

Percentile

Pharmaceuticals

Industry

of 861

Rank

Percentile

Biotechnology

Subindustry

of 371

Rank

Percentile

To view Agios Pharmaceuticals’s complete esg history, request access »

Agios Pharmaceuticals FAQs

  • When was Agios Pharmaceuticals founded?

    Agios Pharmaceuticals was founded in 2007.

  • Where is Agios Pharmaceuticals headquartered?

    Agios Pharmaceuticals is headquartered in Cambridge, MA.

  • What is the size of Agios Pharmaceuticals?

    Agios Pharmaceuticals has 488 total employees.

  • What industry is Agios Pharmaceuticals in?

    Agios Pharmaceuticals’s primary industry is Pharmaceuticals.

  • Is Agios Pharmaceuticals a private or public company?

    Agios Pharmaceuticals is a Public company.

  • What is Agios Pharmaceuticals’s stock symbol?

    The ticker symbol for Agios Pharmaceuticals is AGIO.

  • What is the current stock price of Agios Pharmaceuticals?

    As of 17-Apr-2025 the stock price of Agios Pharmaceuticals is $27.66.

  • What is the current market cap of Agios Pharmaceuticals?

    The current market capitalization of Agios Pharmaceuticals is $1.58B.

  • What is Agios Pharmaceuticals’s current revenue?

    The trailing twelve month revenue for Agios Pharmaceuticals is $36.5M.

  • Who are Agios Pharmaceuticals’s competitors?

    Cue Biopharma, Nektar Therapeutics, ArriVent Biopharma, Dicerna Pharmaceuticals, and BeiGene are some of the 58 competitors of Agios Pharmaceuticals.

  • What is Agios Pharmaceuticals’s annual earnings per share (EPS)?

    Agios Pharmaceuticals’s EPS for 12 months was $11.86.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »